Molecular Targeted Therapy: Novel Therapeutic Approach for Head and Neck Cancer

References

• Vigneswaran N , WilliamsMD. Epidemiologic trends in head and neck cancer and aids in diagnosis. Oral. Maxillofac. Surg. Clin. North. Am.26, 123–141 (2014).
   PubMed Web of Science ®Google Scholar
• Hashibe M , BrennanP , ChuangSCet al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the international head and neck cancer epidemiology consortium. Cancer Epidemiol. Biomarkers Prev.18, 541–550 (2009).
   PubMed Web of Science ®Google Scholar
• Fung C , GrandisJR. Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert. Opin. Emerg. Drugs15, 355–373 (2010).
   PubMed Web of Science ®Google Scholar
• Adelstein D , GillisonML , PfisterDGet al. NCCN Guidelines insights: head and neck cancers, version 2.2017. J. Natl Compr. Canc. Netw.15, 761–770 (2017).
   PubMed Web of Science ®Google Scholar
• Timar J , CsukaO , RemenarEet al. Progression of head and neck squamous cell cancer. Cancer Metastasis Rev.24, 107–127 (2005).
   PubMed Web of Science ®Google Scholar
• Chung WH , ChangDK , Chia-TingH. Targeted therapy for cancer. Cancer2, 57–66 (2006).
   Google Scholar
• Bonner JA , HarariPM , GiraltJet al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med.354, 567–578 (2006).
   PubMed Web of Science ®Google Scholar
• Capdevila J , ElezE , MacarullaT , RamosFJ , Ruiz-EcharriM , TaberneroJ. Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment. Cancer Treat. Rev.35, 354–363 (2009).
   PubMed Web of Science ®Google Scholar
• Cohen EE , RosenF , StadlerWMet al. Phase II Trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol.21, 1980–1987 (2003).
   PubMed Web of Science ®Google Scholar
• Agulnik M , CohenEW , CohenRBet al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J. Clin. Oncol.25, 3978–3984 (2007).
   PubMed Web of Science ®Google Scholar
• Choong NW , KozloffM , TaberDet al. Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Invest. New Drugs28, 677–683 (2010).
   PubMed Web of Science ®Google Scholar
• Saura C , BaselgaJ , HerbstRet al. Antitumor activity of cediranib in patients with metastatic or recurrent head and neck cancer (HNC) or recurrent nonsmall cell lung cancer (NSCLC): an open-label exploratory study. J. Clin. Oncol.6023, 27 (2009).
   Google Scholar
• Seiwert TY , HarafDJ , CohenEEet al. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J. Clin. Oncol.26, 1732–1741 (2008).
   PubMed Web of Science ®Google Scholar
• Argiris A , LiS , SavvidesPet al. Phase III randomized trial of chemotherapy with or without bevacizumab in patients with recurrent or metastatic head and neck cancer. J. Clin. Oncol.37, 3266–3274 (2019).
   PubMedGoogle Scholar
• Yoo GH , MoonJ , LeBlanc Met al. A Phase II trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx and larynx: report of the southwest oncology group. Arch. Otolaryngol. Head Neck Surg.135, 869–874 (2009).
   PubMedGoogle Scholar
• Leidner RS , BellRB. Ipilimumab for head and neck cancer patients. (2016). https://clinicaltrials.gov/ct2/show/NCT02812524
   Google Scholar
• Heseih CY . Rituximab plus chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma. (2020). www.clinicaltrials.gov/ct2/show/NCT04361409
   Google Scholar
• Oh DY , BangYJ. HER2-targeted therapies-a role beyond breast cancer. Nat. Rev. Clin. Oncol.17, 33–48 (2020).
   PubMed Web of Science ®Google Scholar
• Ferguson FM , GrayNS. Kinase inhibitors: the road ahead. Nat. Rev. Drug Discov.17, 353–377 (2018).
   PubMed Web of Science ®Google Scholar
• Arteaga CL , EngelmanJA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell25, 282–303 (2014).
   PubMed Web of Science ®Google Scholar
• Wilson CY , ToliasP. Recent advances in cancer drug discovery targeting RAS. Drug Discov. Today21, 1915–1919 (2016).
   PubMed Web of Science ®Google Scholar
• Chorawala MR , OzaPM , ShahGB. Mechanism of anticancer drug resistance: an overview. Int. J. Pharmaceut. Drug Res.4, 1–9 (2012).
   PubMedGoogle Scholar
• Hanahan D , WeinbergRA. Hallmarks of cancer: the next generation. Cell144, 646–674 (2011).
   PubMed Web of Science ®Google Scholar
• Gimenez-Bonafe P , TortosaA , Perez-TomasR. Overcoming drug resistance by enhancing apoptosis of tumor cells. Curr. Cancer Drug Targ.9, 320–340 (2009).
   PubMed Web of Science ®Google Scholar
• Zahreddine H , BordenKL. Mechanisms and insights into drug resistance in cancer. Front. Pharmacol.4, 28(.2013).
   PubMed Web of Science ®Google Scholar
• Holohan C , van SchaeybroeckS , LongleyDBet al. Cancer drug resistance: an evolving paradigm. Nat. Rev.13, 714–726 (2013).
   Google Scholar
• Kirkin V , JoosS , ZornigM. The role of Bcl-2 family members in tumorigenesis. Biochem. Biophys. Acta1644, 229–249 (2004).
   PubMed Web of Science ®Google Scholar
• Ughachukwu PO , UnekwePC. Efflux Pump mediated resistance in chemotherapy. Ann. Med. Health. Sci. Res.2, 191–198 (2012).
   PubMedGoogle Scholar
• Poole K . Efflux pumps as antimicrobial resistance mechanisms. Ann. Med.39, 162–176 (2007).
   PubMed Web of Science ®Google Scholar
• Baselga J , TrigoJM , BourhisJet al. A Phase II multicenter study of the anti epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab in combination with platinum based chemotherapy in patients with platinum refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck (SCCHN). J. Clin. Oncol.23, 5568 5577 (2005).
   PubMed Web of Science ®Google Scholar
• Eck MJ , ManleyPW. The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl. Curr. Opin. Cell Biol.21, 288–295 (2009).
   PubMed Web of Science ®Google Scholar
• Hochhaus A , LaRosee P , MullerMCet al. Impact of BCR-ABL mutations on patients with chronic myeloid leukemia. Cell Cycle10, 250–260 (2011).
   PubMed Web of Science ®Google Scholar
• Kornev AP , HasteNM , TaylorSSet al. Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proc. Natl Acad Sci. USA103, 17783–17788 (2006).
   PubMed Web of Science ®Google Scholar
• Friedberg EC . Out of the shadows and into the light: the emergence of DNA repair. Trends Biochem. Sci.20, 381 (1995).
   PubMed Web of Science ®Google Scholar
• Rosenberg B , VanCampL , TroskoJEet al. Platinum compounds: a new class of potent antitumour agents. Nature222, 385–386 (1969).
   PubMed Web of Science ®Google Scholar
• Kelland L . The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer7, 573–584 (2007).
   PubMed Web of Science ®Google Scholar
• Bausorakos SP , LiL , AparicioAMet al. Combination platinum-based and DNA damage response-targeting cancer therapy: evolution and future directions. Curr. Med. Chem.24(15), 1586–1606 (2017).
   PubMed Web of Science ®Google Scholar
• Caulson A , LevyA , Gossel-WilliamsM. Monoclonal antibodies in cancer therapy: mechanisms, success and limitations. West Indian Med. J.63, 650–654 (2014).
   PubMed Web of Science ®Google Scholar
• Reichert JM , RosensweigCJ , FadenLBet al. Monoclonal antibody successes in the clinic. Nat. Biotechnol.23, 1073–1078 (2005).
   PubMed Web of Science ®Google Scholar
• Quak J , GerretsenM , BreeRDet al. Perspectives of monoclonal antibodies for detection and treatment of head and neck tumours. Anticancer Res.13, 2533–2539 (1996).
   Google Scholar
• Sharkey RM , GoldenbergDM. Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J. Clin.56, 226–243 (2006).
   PubMed Web of Science ®Google Scholar
• Liu J , YuanY , ChenWet al. Immune check point proteins VISTA and PD-1 non redundantly regulate murine T-cell responses. Proc. Natl Acad. Sci. USA26, 6682–6687 (2015).
   Google Scholar
• Hargadon KM , JohnsonCE , WilliamsCJ. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int. Immunopharmacol.62, 29–39 (2018).
   PubMed Web of Science ®Google Scholar
• Du X , TangF , LiuM , SuJ , ZhangYet al. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy. Cell Res.28, 416–432 (2018).
   PubMed Web of Science ®Google Scholar
• Vokes EE , WeichselbaumRR , LippmanSMet al. Head and neck cancer. N. Engl. J. Med.328, 184–194 (1993).
   PubMed Web of Science ®Google Scholar
• Colnot DR , QuakJJ , RoosJCet al. Radioimmunotherapy in patients with head and neck squamous cell carcinoma: initial experience. Head Neck23, 559–565 (2001).
   PubMed Web of Science ®Google Scholar
• Sharkey RM , GoldenbergDM. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J. Nucl. Med.46, 115–1127 (2005).
   PubMed Web of Science ®Google Scholar
• Hamblett KJ , SenterPD , ChaceDFet al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin. Cancer Res.15, 7063–7070 (2004).
   Google Scholar
• Hamann PR , HinmanLM , HollanderIet al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Lancet19, 176–182 (2002).
   Google Scholar
• Giles FJ . Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia. Expert. Rev. Anticancer Ther.2, 630–640 (2002).
   PubMedGoogle Scholar
• Brinkmann U , KontermannRE. The making of bispecific antibodies. mAbs9, 182–212 (2017).
   PubMed Web of Science ®Google Scholar
• Spiess C , ZhaiQ , CarterPJ. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol. Immunol.67, 95–106 (2015).
   PubMed Web of Science ®Google Scholar
• Herbst RS , ArquetteM , ShinDMet al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J. Clin. Oncol.23, 5578–5587 (2005).
   PubMed Web of Science ®Google Scholar
• Crater P . Improving the efficacy of antibody based cancer therapies. Nat. Rev. Cancer1, 118–129 (2001).
   PubMed Web of Science ®Google Scholar
• Gonzalez H , HagerlingC , WerbZ. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev.32, 1267–1284 (2018).
   PubMed Web of Science ®Google Scholar
• Borcoman E , KanjanapanY , ChampiatSet al. Novel patterns of response under immunotherapy. Ann. Oncol.30, 385–396 (2019).
   PubMed Web of Science ®Google Scholar
• Pardoll DM . The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer12, 252–264 (2012).
   PubMed Web of Science ®Google Scholar
• Chamoto K , Al-HabsiM , HonjoT. Role of PD-1 in immunity and diseases. Curr. Top. Microbiol. Immunol.410, 75–79 (2017).
   PubMed Web of Science ®Google Scholar
• Okazaki T , HonjoT. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol.27, 195–201 (2006).
   PubMed Web of Science ®Google Scholar
• Soulieres D , SenzerNN , VokesEEet al. Multicenter Phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J. Clin. Oncol.22, 77–85 (2004).
   PubMed Web of Science ®Google Scholar
• Cohen EE , KaneMA , ListMet al. Phase II study of 250 mg gefitinib in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). Clin. Cancer Res.11, 8418–8424 (2005).
   PubMed Web of Science ®Google Scholar
• Boltz K . Pazopanib/cetuximab combo shows promising efficacy in advanced HNSCC. Invest. New Drugs33, 1248–1256 (2015).
   PubMedGoogle Scholar
• Rossari F , MinutoloF , OrciuoloE. Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy. J. Haematol. Oncol.11, 18 (2015).
   Google Scholar
• Arteaga CL . Epidermal growth factor receptor dependence in human tumors: more than just expression?Oncologist7(Suppl. 4), 31–39 (2007).
   Google Scholar
• Bhattacharya B , AdhikaryS , BasuJet al. A prospective randomised controlled trial of concurrent chemoradiation versus concurrent chemoradiation along with gefitinib in locally advanced squamous cell carcinoma of head and neck. Clin. Cancer Invest. J.3, 146–152 (2014).
   Google Scholar
• Schreck KC , GrossmanSA , PratilasCA. BRAF mutations and the utility of RAF and MEK inhibitors in primary brain tumors. Cancers (Basel.)11, 1262–1284 (2019).
   PubMed Web of Science ®Google Scholar
• Swiecicki PL , SpectorM , WordenFP. Axitinib in the treatment of head and neck malignancies. Curr. Clin. Pharmacol.11, 72–76 (2016).
   PubMedGoogle Scholar
• Affolter A , SamosnyG , HeimesASet al. Multikinase inhibitors sorafenib and sunitinib as radiosensitizers in head and neck cancer cell lines. Head Neck39, 623–632 (2017).
   PubMed Web of Science ®Google Scholar
• Kies MS , GardenAS , HolsingerSet al. Induction chemotherapy (CT) with weekly paclitaxel, carboplatin, and cetuximab for squamous cell carcinoma of the head and neck (HN). ASCO Proceedings24(Suppl. 18), 5520 (2006).
   Google Scholar
• Vermorken B , MesiaR , RiveraFet al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. New. Eng. J. Med.350, 1116–1127 (2008).
   Google Scholar
• Jimeno A , ShiraiK , ChoiMet al. A randomized, Phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer. Ann.Oncol.26(3), (2015).
   Web of Science ®Google Scholar
• Bourhis J , RiveraF , MesiaRet al. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol.24, 2866–2872 (2006).
   PubMed Web of Science ®Google Scholar
• Bossi P , MiceliR , LocatiLDet al. A randomized, Phase II study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann. Oncol.28, 2820–2826 (2017).
   PubMed Web of Science ®Google Scholar
• Subramanian S , SridharanN , BalasundaramVet al. Efficacy and safety of nimotuzumab in unresectable, recurrent, and/or metastatic squamous cell carcinoma of the head and neck: a hospital-based retrospective evidence. South Asian J. Cancer7, 188–192 (2018).
   PubMedGoogle Scholar
• Adkins D , LeyJ , NeupaneP , WordenFet al. Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, Phase II trial. Lancet Oncol.20, 1295–1298 (2019).
   PubMed Web of Science ®Google Scholar
• de Souza JA , DavisDW , ZhangYet al. A Phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin. Cancer Res.18, 2336–2343 (2012).
   PubMed Web of Science ®Google Scholar
• Suda K , MitsudomiT. Development of molecular targeted therapies in lung cancer. Nihon Geka Gakkai Zasshi115, 130–136 (2014).
   PubMedGoogle Scholar
• Yano S . Molecular mechanisms of targeted drug resistance in lung cancer and its therapeutic strategy. Nishon Rinsho73, 1378–1383 (2015).
   PubMedGoogle Scholar
• Napier MP , SharmaSK , SpringerCJet al. Advances in brief antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma. Clin. Cancer Res.6, 765–772 (2000).
   PubMed Web of Science ®Google Scholar
• Schepelmann S , HallenbeckP , OgilivieLM. Systemic gene-directed enzyme prodrug therapy of hepatocellular carcinoma using a targeted adenovirus armed with carboxypeptidase G2. Cancer Res.65, 5003–5008 (2005).
   PubMed Web of Science ®Google Scholar
• Singh Y , PalomboM , SinkoPJ. Recent trends in targeted anticancer prodrug and conjugate design. Curr. Med. Chem.15, 1802–1826 (2008).
   PubMed Web of Science ®Google Scholar
• Kratz F , MüllerIA , RyppaCet al. Prodrug strategies in anticancer chemotherapy. Chem. Med. Chem.3, 20–53 (2008).
   Google Scholar
• Mendes RA , CarvalhoFC , VanderwaalI. An overview on the expression of cyclooxygenase-2 in tumors of the head and neck. Oral Oncol.45, 124–128 (2009).
   Web of Science ®Google Scholar
• Rahman MA , AminARMR , ShinDM. Chemopreventive potential of natural compounds in head and neck cancer. Nutr. Cancer62, 973–987 (2010).
   PubMed Web of Science ®Google Scholar
• Silvermann NA , AlexanderJCJr , ChreitinPB. CEA levels in head and neck cancer. Cancer37, 2204–2211 (1976).
   PubMed Web of Science ®Google Scholar
• Kass ES , GreinerJW , KantorJAet al. Carcinoembryonic antigen as a target for specific antitumor immunotherapy of head and neck cancer. Cancer Res.62, 5049–5057 (2002).
   PubMed Web of Science ®Google Scholar
• Cole AJ , YangVC , DavidAE. Cancer theranostics: the rise of magnetic targeted nanoparticles. Trends Biotechnol.29, 323–332 (2011).
   PubMed Web of Science ®Google Scholar
• Chari RV , MillerML , WiddisonWC. Antibody-drug conjugates: an emerging concept in cancer therapy. Angew. Chem. Int. Ed.53, 3796–3827 (2014).
   PubMed Web of Science ®Google Scholar
• Ma W , CheethamAG , CuiH. Building nanostructures with drugs. Nano Today11, 13–30 (2016).
   PubMed Web of Science ®Google Scholar
• Wang D , FeiB , HaligLVet al. Photodynamic therapy (PDT) is a highly specific anticancer treatment modality for various cancers, particularly for recurrent cancers that no longer respond to conventional anticancer therapies. ACS Nano22, 6620–6632 (2014).
   Google Scholar